GIA
GALT icon

Gladstone Institutional Advisory’s Galectin Therapeutics GALT Stock Holding History

Gladstone Institutional Advisory’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Hold
23,900
– – ﹤0.01% 876
2026
Q1 		$66.7K Hold
23,900
– – ﹤0.01% 823
2025
Q4 		$99.4K Sell
23,900
-750
-3% -$3.95K ﹤0.01% 776
2025
Q3 		$104K Hold
24,650
– – ﹤0.01% 771
2025
Q2 		$52K Hold
24,650
– – ﹤0.01% 748
2025
Q1 		$30.1K Hold
24,650
– – ﹤0.01% 713
2024
Q4 		$31.8K Buy
24,650
+2,900
+13% +$6.95K ﹤0.01% 695
2024
Q3 		$59.8K Buy
+21,750
New +$53.4K ﹤0.01% 674

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Gladstone Institutional Advisory's GALT Position: Q2 2026 in Review

Gladstone Institutional Advisory held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 23,900 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #876.

Gladstone Institutional Advisory first reported a position in GALT in Q3 2024 and has held it in 8 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Gladstone Institutional Advisory held 23,900 shares of Galectin Therapeutics worth $111K as of Q2 2026.
  • Gladstone Institutional Advisory left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Gladstone Institutional Advisory's portfolio in Q2 2026, its #876 holding.
  • Gladstone Institutional Advisory first reported a position in Galectin Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.